
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    1. Key functional markers and pathways<br><br>I‚Äôll first group the most informative genes by function, with emphasis on brain/immune/vascular context.<br><br>**a. Chemokines / inflammatory mediators**<br>- **CCL3L1, CCL3, CCL4, CCL4L2, CXCL8 (IL-8)**  <br>  Strong pro‚Äëinflammatory chemokines, typically produced by activated myeloid cells (monocytes/macrophages/microglia) and some T cells. CCL3/4 are classic macrophage/monocyte activation markers; CXCL8 is a hallmark of activated inflammatory myeloid cells.<br>- **IL1B**  <br>  Canonical pro‚Äëinflammatory cytokine, strongly induced in activated macrophages/microglia.<br><br>**b. Complement and innate immune receptors**<br>- **C1QA, C1QB**  <br>  Components of C1q, highly expressed in tissue macrophages and microglia; in brain, C1QA/B are classic microglia/macrophage markers.<br>- **C3AR1, C5AR1**  <br>  Receptors for complement C3a and C5a, respectively; strongly associated with myeloid lineage (monocytes/macrophages/microglia, neutrophils). Their co‚Äëexpression with C1Q genes indicates a complement‚Äëresponsive phagocyte.<br>- **CSF1R**  <br>  Colony stimulating factor 1 receptor; essential for survival and differentiation of macrophages and microglia. A core microglia/macrophage marker in brain.<br><br>**c. Antigen presentation / MHC class II**<br>- **HLA-DRA, HLA-DQA2, HLA-DPA1, HLA-DPB1, CD74**  <br>  MHC class II genes and invariant chain (CD74). These define professional antigen‚Äëpresenting cells (APCs): macrophages, dendritic cells, B cells. In brain, microglia and perivascular macrophages upregulate these under activation/inflammation.<br><br>**d. Scavenger / phagocytic / tissue macrophage markers**<br>- **CD163**  <br>  Hemoglobin‚Äìhaptoglobin scavenger receptor; hallmark of tissue macrophages, especially perivascular macrophages and M2‚Äëlike macrophages. In brain, CD163 is strongly associated with perivascular and meningeal macrophages, not homeostatic parenchymal microglia.<br>- **MRC1 (CD206)**  <br>  Mannose receptor; classic M2‚Äëlike tissue macrophage marker, enriched in perivascular/meningeal macrophages and some border‚Äëassociated macrophages in CNS.<br>- **MS4A7, MS4A6A**  <br>  Myeloid membrane proteins; MS4A7 is enriched in monocytes/macrophages; MS4A6A is also myeloid‚Äëassociated. Both are common in tissue macrophages and some microglia subsets.<br>- **GPR183 (EBI2)**  <br>  Oxysterol receptor; expressed in B cells and myeloid cells, including microglia and border‚Äëassociated macrophages; involved in positioning within tissues.<br>- **P2RY13**  <br>  Purinergic receptor; expressed in microglia and macrophages, involved in sensing extracellular nucleotides.<br>- **CYP26B1**  <br>  Retinoic acid‚Äìmetabolizing enzyme; expressed in some macrophage subsets and stromal cells; can be induced in tissue macrophages in specific niches.<br><br>**e. Vascular / perivascular / contractile / endothelial‚Äëassociated markers**<br>- **RGS5**  <br>  Regulator of G‚Äëprotein signaling 5; canonical pericyte and vascular smooth muscle cell marker. Often marks mural cells (pericytes, vascular smooth muscle) in brain vasculature.<br>- **GJA4 (Connexin 37)**  <br>  Gap junction protein; expressed in endothelial cells and some vascular‚Äëassociated cells, including perivascular macrophages in some datasets.<br>- **ANGPT1**  <br>  Angiopoietin‚Äë1; involved in vascular stabilization and endothelial‚Äìpericyte interactions; can be expressed by pericytes and perivascular stromal/macrophage populations.<br>- **TRPC6**  <br>  Cation channel; expressed in podocytes, some endothelial and smooth muscle cells, and occasionally in perivascular macrophages.<br>- **MRVI1**  <br>  NO/cGMP‚Äëregulated protein; enriched in smooth muscle and some myeloid cells; often appears in vascular‚Äëassociated myeloid clusters.<br>- **HRC (Histidine‚Äërich Ca2+ binding protein)**  <br>  Ca2+ handling protein; more typical of muscle/cardiac tissue but can appear in vascular‚Äëassociated cells.<br>- **REM1, RERG, RERGL, FRMD3, FILIP1L, TINAGL1, TIMP4, ANO1**  <br>  A set of genes often enriched in vascular/perivascular stromal or mural cells (e.g., ANO1 in smooth muscle/pericytes; TIMP4 in vascular remodeling; TINAGL1, FILIP1L, FRMD3 in extracellular matrix/adhesion contexts). Their co‚Äëexpression with RGS5 and GJA4 suggests a perivascular niche.<br><br>**f. Lipid metabolism / scavenging / stromal interaction**<br>- **CD36**  <br>  Scavenger receptor for lipids and oxidized LDL; expressed in macrophages, microglia, endothelial cells, and pericytes. In brain, CD36 is common in microglia and perivascular macrophages.<br>- **FABP4**  <br>  Fatty acid binding protein 4; classic adipocyte and some macrophage subsets (especially inflammatory and perivascular macrophages). In brain, FABP4+ macrophages are typically perivascular/border‚Äëassociated, not parenchymal microglia.<br>- **IGFBP7**  <br>  IGF‚Äëbinding protein; expressed in endothelial cells, pericytes, and some macrophages; associated with vascular niches.<br>- **AGT (Angiotensinogen)**  <br>  Component of renin‚Äìangiotensin system; expressed in astrocytes and vascular‚Äëassociated cells; can also be expressed by perivascular macrophages in some contexts.<br>- **STEAP4**  <br>  Metalloreductase; induced in inflammatory and metabolic macrophages, including perivascular adipose tissue macrophages.<br><br>**g. Other immune / regulatory markers**<br>- **FCGBP**  <br>  Fc fragment binding protein; often in mucosal/secretory cells but also in some macrophage subsets.<br>- **CYP26B1, CYGB**  <br>  CYGB (Cytoglobin) is expressed in pericytes, fibroblasts, and some macrophages; associated with hypoxia/vascular niches.<br>- **GPR183, P2RY13** (already noted) further support a myeloid, tissue‚Äëresident, chemotactic phenotype.<br><br>**h. Neuronal/other markers**<br>- **HTR1F**  <br>  5‚ÄëHT1F serotonin receptor; typically neuronal, but low‚Äëlevel expression can appear in vascular/perivascular cells or macrophages in scRNA‚Äëseq; here it‚Äôs likely not defining the lineage.<br>- **IGSF21**  <br>  Immunoglobulin superfamily member; described in neurons/synapses, but low expression in non‚Äëneuronal cells is possible; again, not lineage‚Äëdefining here.<br>- **FHL5, ANKRD22**  <br>  More generic regulatory proteins; ANKRD22 is often induced in activated immune cells, including macrophages.<br><br>Overall, the functional profile is: **highly inflammatory, complement‚Äëactive, MHC‚ÄëII+ phagocytes with strong perivascular/vascular‚Äëassociated signatures and lipid handling**.<br><br>---<br><br>2. Key cell type markers (tissue/lineage)<br><br>**Myeloid / macrophage / microglia lineage markers**<br>- **CSF1R, C1QA, C1QB, C3AR1, C5AR1, CD163, MRC1, MS4A7, MS4A6A, GPR183, P2RY13, IL1B, CCL3/4, CXCL8, CCL3L1, CCL4L2, HLA‚ÄëDRA/DQA2/DPA1/DPB1, CD74, STEAP4, CD36, FABP4, AGT, CYGB**  <br>  This constellation is strongly myeloid and specifically **tissue macrophage** rather than neutrophil or dendritic cell. The presence of C1QA/B and CSF1R is particularly characteristic of microglia/macrophage lineage in brain.<br><br>**Perivascular / border‚Äëassociated macrophage vs parenchymal microglia**<br>- **CD163, MRC1 (CD206), FABP4, IGFBP7, ANGPT1, RGS5, GJA4, CYGB, TINAGL1, TIMP4, TRPC6, MRVI1, ANO1, STEAP4**  <br>  In human brain scRNA‚Äëseq atlases, **CD163+ MRC1+ FABP4+** macrophages are consistently annotated as **perivascular or border‚Äëassociated macrophages (BAMs)**, distinct from homeostatic parenchymal microglia (which are typically P2RY12+, TMEM119+, CX3CR1+, SALL1+, and usually CD163‚Äì MRC1‚Äì FABP4‚Äì).  <br>  The co‚Äëexpression of vascular/mural markers (RGS5, GJA4, ANGPT1, CYGB, etc.) further supports a **perivascular niche**.<br><br>**Exclusion of other major brain cell types**<br>- **Not astrocytes**: No GFAP, AQP4, SLC1A2, ALDH1L1, SLC1A3.<br>- **Not neurons**: No NEUN (RBFOX3), SNAP25, SYT1, MAP2, etc.; HTR1F alone is insufficient and likely ectopic/low‚Äëlevel.<br>- **Not oligodendrocytes/OPCs**: No MBP, PLP1, MOG, PDGFRA, OLIG1/2.<br>- **Not endothelial cells**: Some vascular markers (GJA4, ANGPT1) are present, but the dominant signature is myeloid (CSF1R, C1Q, chemokines, MHC‚ÄëII, CD163, MRC1).<br>- **Not classical dendritic cells**: While MHC‚ÄëII is high, the strong C1Q/CSF1R/CD163/MRC1/MS4A7 profile is more macrophage‚Äëlike than cDC‚Äëlike; no clear FLT3, IRF8, BATF3, etc.<br><br>---<br><br>3. Cross‚Äëreference with known scRNA‚Äëseq brain atlases / literature<br><br>Using patterns from major human brain scRNA‚Äëseq resources:<br><br>- **Olah et al., Nat Neurosci 2020; Sankowski et al., Nat Neurosci 2019; Masuda et al., Nat Neurosci 2019; Van Hove et al., Cell 2019; Yang et al., Nature 2022 (human brain atlases)**  <br>  These studies consistently distinguish:<br>  - **Parenchymal microglia**: P2RY12+, TMEM119+, CX3CR1+, SALL1+, C1QA/B+, CSF1R+, usually CD163‚Äì MRC1‚Äì FABP4‚Äì.<br>  - **Perivascular / meningeal / choroid plexus macrophages (border‚Äëassociated macrophages, BAMs)**: **CD163+, MRC1+, FABP4+, MS4A7+, MS4A6A+**, often with **IGFBP7, CYGB, GJA4, RGS5** and other vascular‚Äëassociated genes. They can be strongly MHC‚ÄëII+ and chemokine‚Äëproducing (CCL3/4, CXCL8, IL1B) under activation.<br><br>- **Human brain vascular/perivascular atlases (e.g., Vanlandewijck et al., Nature 2018; Yang et al., Cell 2022)**  <br>  Show **RGS5, GJA4, CYGB, ANGPT1, TINAGL1, TIMP4** in pericytes and perivascular stromal cells, and **CD163+ MRC1+ macrophages** closely associated with these vascular markers, forming a perivascular macrophage cluster.<br><br>- **FABP4+ macrophages** are repeatedly annotated as **perivascular or border‚Äëassociated macrophages** in human and mouse CNS datasets, not as parenchymal microglia.<br><br>The combination **CD163+ MRC1+ FABP4+ MS4A7+ C1QA/B+ CSF1R+** with **RGS5+ GJA4+ CYGB+ IGFBP7+** is a textbook signature of **perivascular/border‚Äëassociated macrophages** in human brain scRNA‚Äëseq atlases.<br><br>---<br><br>4. Most probable general cell type<br><br>Given:<br><br>- Strong myeloid/macrophage signature (CSF1R, C1QA/B, C3AR1, C5AR1, MS4A7, MS4A6A, chemokines, IL1B).<br>- Professional APC profile (MHC‚ÄëII genes + CD74).<br>- Tissue‚Äëresident, scavenger phenotype (CD163, MRC1, CD36).<br>- Vascular/perivascular association (RGS5, GJA4, ANGPT1, CYGB, IGFBP7, FABP4, TIMP4, TINAGL1).<br><br>**General cell type: Tissue‚Äëresident macrophage (brain‚Äëresident myeloid cell), specifically a border‚Äëassociated/perivascular macrophage rather than parenchymal microglia.**<br><br>---<br><br>5. Top 3 most probable sub‚Äëcell types (ranked)<br><br>Within the broad category of **brain‚Äëresident myeloid cells**, the three most plausible subtypes are:<br><br>### 1) Perivascular / border‚Äëassociated macrophages (BAMs) ‚Äì **most likely**<br><br>**Supporting markers:**<br>- **CD163, MRC1 (CD206)**: Canonical perivascular/meningeal macrophage markers in CNS.<br>- **FABP4, IGFBP7, CYGB**: Strongly enriched in perivascular/border‚Äëassociated macrophages in human brain atlases.<br>- **RGS5, GJA4, ANGPT1, TINAGL1, TIMP4, TRPC6, MRVI1, ANO1**: Vascular/perivascular niche and mural cell‚Äìassociated genes, consistent with cells residing at the vessel wall.<br>- **C1QA/B, CSF1R, MS4A7, MS4A6A, C3AR1, C5AR1**: Tissue macrophage/myeloid identity.<br>- **HLA‚ÄëDRA/DQA2/DPA1/DPB1, CD74, IL1B, CCL3/4, CXCL8**: Activated, antigen‚Äëpresenting, inflammatory macrophage phenotype, which is common for perivascular macrophages in inflamed or diseased brain.<br><br>**Against pure parenchymal microglia:**<br>- Lack of classic microglia‚Äëspecific markers (P2RY12, TMEM119, SALL1, CX3CR1) in the top list.<br>- Presence of CD163, MRC1, FABP4, which are typically absent or very low in homeostatic microglia.<br><br>**Conclusion:** This cluster best matches **CD163+ MRC1+ FABP4+ perivascular/border‚Äëassociated macrophages**.<br><br>---<br><br>### 2) Inflammatory / disease‚Äëassociated microglia‚Äëlike macrophages ‚Äì **second most likely**<br><br>One could consider that these are **microglia‚Äëderived cells** that have acquired a perivascular‚Äëlike, highly activated phenotype (e.g., in neuroinflammation, tumor, or neurodegeneration):<br><br>**Supporting points:**<br>- Strong microglia/macrophage core: **C1QA/B, CSF1R, C3AR1, C5AR1, GPR183, P2RY13**.<br>- High inflammatory chemokines and cytokines: **CCL3/4, CXCL8, IL1B**.<br>- High MHC‚ÄëII: **HLA‚ÄëDRA/DQA2/DPA1/DPB1, CD74**.<br><br>**Against this being ‚Äúclassical‚Äù microglia:**<br>- The **CD163+ MRC1+ FABP4+** profile is much more typical of border‚Äëassociated/perivascular macrophages than of microglia, even in disease.<br>- Vascular markers (RGS5, GJA4, ANGPT1) are more consistent with perivascular localization.<br><br>Thus, while they are microglia‚Äëlineage‚Äìrelated myeloid cells, the more precise annotation is perivascular/BAM rather than parenchymal microglia.<br><br>---<br><br>### 3) Perivascular macrophage subset with strong vascular/mural gene co‚Äëexpression ‚Äì **third most likely (a finer subtype)**<br><br>Within perivascular macrophages, several subclusters are often described:<br><br>- **CD163+ MRC1+ FABP4hi IGFBP7+ ‚Äúvascular‚Äëinteracting‚Äù macrophages** with strong expression of **RGS5, GJA4, CYGB, ANGPT1, TIMP4, TINAGL1**.<br>- More ‚Äúimmune‚Äëfocused‚Äù BAMs with higher chemokine/cytokine output.<br><br>Given the high ranking of **RGS5, GJA4, ANGPT1, CYGB, TIMP4, TINAGL1** alongside **CD163, MRC1, FABP4**, this cluster likely corresponds to a **perivascular macrophage subset tightly integrated with the vascular wall**, sometimes annotated as:<br>- ‚ÄúPerivascular macrophages (vascular‚Äëassociated BAMs)‚Äù<br>- ‚ÄúCD163+ MRC1+ FABP4+ perivascular macrophages‚Äù<br>- Or ‚Äúvascular BAMs‚Äù in some atlases.<br><br>This is essentially a refinement of (1), but if one wanted three distinct labels, this would be a **vascular‚Äëinteracting perivascular macrophage subset**.<br><br>---<br><br>**Most likely subtype (final call)**<br><br>Putting all evidence together:<br><br>- Lineage: Myeloid, macrophage.<br>- Brain context: Resident, non‚Äëparenchymal, vascular‚Äëassociated.<br>- Phenotype: CD163+ MRC1+ FABP4+ C1QA/B+ CSF1R+ MHC‚ÄëII+ inflammatory chemokine‚Äëproducing.<br><br>**Final annotation:  <br>‚ÄúPerivascular / border‚Äëassociated macrophages (CD163+ MRC1+ FABP4+ brain‚Äëresident macrophages)‚Äù**<br><br>---<br><br>6. Concise summary<br><br>This cluster expresses a strong myeloid/macrophage program (CSF1R, C1QA/B, C3AR1, C5AR1, MS4A7/6A), high MHC‚ÄëII (HLA‚ÄëDRA/DQA2/DPA1/DPB1, CD74), and robust inflammatory chemokines/cytokines (CCL3/4, CXCL8, IL1B). The presence of **CD163, MRC1, FABP4, IGFBP7, CYGB** together with vascular/mural markers (**RGS5, GJA4, ANGPT1, TIMP4, TINAGL1**) is characteristic of **perivascular/border‚Äëassociated macrophages** in human brain scRNA‚Äëseq atlases, and distinct from parenchymal microglia.  <br><br>Therefore, the most appropriate annotation is: **Perivascular (border‚Äëassociated) macrophages, CD163+ MRC1+ FABP4+ subtype.**<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Perivascular / border-associated macrophages (brain-resident tissue macrophages)</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>CD163+ MRC1+ FABP4+ perivascular/border-associated macrophages</li><li>Inflammatory, MHC-II+ brain-resident myeloid macrophages</li><li>Vascular-interacting perivascular macrophage subset with strong mural/vascular gene co-expression</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Perivascular/border-associated macrophages with vascular/pericyte-associated gene expression</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">nan</div>
                        <div class="scoring-content">
                            Error: Error code: 400 - {'error': {'message': "Unsupported parameter: 'max_tokens' is not supported with this model. Use 'max_completion_tokens' instead.", 'type': 'invalid_request_error', 'param': 'max_tokens', 'code': 'unsupported_parameter'}}<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    